Navigation Links
Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Date:11/1/2012

evir is being studied in combination with pegylated interferon and ribavirin, and in combination with direct-acting antiviral (DAA) agents in all-oral interferon-free regimens, with and without ribavirin.

Global Phase 3 studies of simeprevir include QUEST-1 and QUEST-2 in treatment-naive patients, PROMISE in patients who have relapsed after prior interferon-based treatment and ATTAIN in treatment-experienced patients. In parallel to these trials, Phase 3 studies for simeprevir are ongoing in both treatment-naive and treatment-experienced HIV-HCV co-infected patients, HCV genotype 4 patients and in Japanese HCV genotype 1 patients.

Simeprevir is also being studied in other Phase 2 interferon-free trials, with and without ribavirin, in combination with:

  • Janssen's TMC647055 and ritonavir in treatment-naive, relapser or null-responder HCV genotype 1 patients;
  • Gilead Sciences, Inc.'s sofosbuvir (GS-7977) in null-responder HCV genotype 1 patients; and
  • Bristol-Myers Squibb's daclatasvir (BMS-790052) in treatment-naive or previous null-responder HCV genotype 1 patients.

For additional information about simeprevir, please visit www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease and liver transplants, is a rapidly evolving treatment area with a clear need for innovative treatments. Approximately 170 to 210 million people are infected with hepatitis C worldwide, with three to four million people newly infected each year.

About Janssen
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative product
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. Watson Announces Global Generics Management Team
8. Watson Announces New Name -- Actavis -- for Global Operations
9. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
(Date:8/27/2015)... WASHINGTON , Aug. 27, 2015 ... Collaborative (BPC) applauds the U.S. Food and Drug ... a distinguishable name in its draft guidance issued ... of biological products proposes distinguishable names, calling for ... includes an FDA-designated suffix. This proposal reflects the ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Dec. 5, 2011  At this week,s 46th Annual Midyear ... Health-System Pharmacists (ASHP), Cardinal Health launched BarCode360™ , ... making it easier, more timely and cost efficient to ... scanned at the patient bedside. ASHP has ...
... Pharmaceutical Co. Ltd, in which European healthcare venture capital ... as one of the Deloitte & Touche,s 50 top-performing ... the past three years. Beijing-headquartered GC-Rise, which ... revenues rising more than 270% on average per annum ...
Cached Medicine Technology:Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 3Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... at a low cost. Personalized with practice contact information and logos, Calendars stand ... offices can also incorporate Calendars into seasonal mailings, thank you and welcome communications, ...
(Date:8/28/2015)... ... ... Northridge dentists Dr. Elyson and Dr. Assili are now offering patients ... a one hour treatment of this teeth whitening option. Zoom whitening is ... features that can turn teeth up to nine shades whiter. Effective on a wide ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, an ... coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® brand’s ... Extraction™ technology, which delivers a variety of sizes and styles while achieving the ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
Breaking Medicine News(10 mins):Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... Acute Myelogenous Leukemia (AML) and those experiencing bone marrow ... transplantation graft failure or engraftment delay,- Bayer will replace current ... supplies of Leukine to current levels as ... HealthCare Pharmaceuticals,Inc. announced today, following consultation with the United States ...
... 23 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... will present at the 2008 Wachovia Healthcare,Conference in Boston ... To access a live audio webcast of the presentation, ... investor relations page of InterMune,s,corporate website at http://www.intermune.com ...
... Year-Round Campaign Continues to Benefit the National Breast ... ... to underbanked,customers, demonstrated desire to adopt and contribute to a cause, ... United,States, and ACE Cash Express, a leading retailer of financial services,have ...
... Alice S. Fisher of the Criminal Division and ... of Florida announced today that,owners of nine separate ... terms within the past two weeks. Collectively, the ... worth of,unnecessary durable medical equipment (DME) and infusion ...
... interdisciplinary team reports the design of chimeric ... for potential application in biomedical research. , ... stage where domains that traditionally belonged to ... are coming together to offer new synergistic ...
... Fewer deaths, heart attacks found in 18-month study , , WEDNESDAY, ... risk of death and heart attacks than stents for people ... study indicates. , The finding is far from the last ... author Dr. Edward L. Hannan, associate dean for research at ...
Cached Medicine News:Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 2Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 3Health News:Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation 4Health News:InterMune to Present at the 2008 Wachovia Healthcare Conference 2Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 2Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 3Health News:NetSpend(R) and ACE Cash Express Customers Keep Thinking Pink With the All-Access(R) Visa(R) Prepaid Card Program 4Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 2Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 3Health News:Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud 4Health News:Engineering chimeric polypeptides to illuminate cellular redox states 2Health News:Surgery Better Than Stents for Multiple Blockages 2Health News:Surgery Better Than Stents for Multiple Blockages 3
... The Chemcard Glucose Test is a simple, ... abnormally high fasting plasma glucose (blood sugar) levels ... Chemcard Glucose is a 3 minute test which ... a fingerstick, requires no instruments, and was shown ...
The Lifestream Plus Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program....
CardioChek™ PA Portable Whole Blood Test System...
... A(ll) Test is a lateral ... rapid, qualitative detection of Group ... swabs. The test is intended ... in the diagnosis of Group ...
Medicine Products: